Clever, Personable, and Unconventional: Pharvaris’ Exciting Business Update and Expanded Development Program for Deucrictibant
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS) Announces Major Developments in HAE Treatment Introduction Pharvaris, a leading biopharmaceutical company, has recently unveiled plans for the groundbreaking CHAPTER-3 Phase 3 study of deucrictibant extended-release tablets. This study aims to revolutionize the prophylactic treatment of hereditary angioedema (HAE) attacks, while also introducing new…